Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma

Histochemistry

Volumn 93, Issue 6, 1990, Pages 559-566

  Kristensen, P ^a   Pyke, C ^a   Lund, L R ^a   Andreasen, P A ^a,b   Dano K ^a  

^a FINSEN LABORATORY   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; HISTOCHEMISTRY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LEWIS CARCINOMA; MAMMAL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMAL; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PLASMINOGEN INACTIVATORS; SUPPORT, NON-U.S. GOV'T; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 0025319263     PISSN: 03015564     EISSN: 1432119X     Source Type: Journal    
DOI: 10.1007/BF00272198     Document Type: Article

References (49)

1. Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing
2. Hormonal regulation of extracellular plasminogen activators and Mr 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies
3. Plasminogen activator inhibitor type-1 biosynthesis and mRNA level are increased by dexamethasone in human fibrosarcoma cells
4. Plasminogen activator inhibitors: hormonally regulated serpins
5. The receptor-binding sequence of urokinase
6. Urokinase-type plasminogen activator: proenzyme, receptor and inhibitors
7. Tissue-type plasminogen activator (t-PA) and singlechain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy
8. Plasminogen activator from cells transformed by an oncogenic virus: inhibitors of the activation reaction
9. Purification and characterization of a plasminogen activator from mouse cells transformed by an oncogenic virus
10. Inhibition of a plasminogen activator from oncogenic virus-transformed mouse cells by rabbit antibodies against the enzyme
11. Plasminogen activators, tissue degradation, and cancer
12. Cell surface plasminogen activation
13. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes
14. Reverse fibrin autoradiography: a method to detect and partially characterize protease inhibitors after sodium dodecyl sulfate-polyacrylamide gel electrophoresis
15. The primary plasminogen activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related
16. Tumor necrosis factor-α regulates mRNA for urokinase-type plasminogen activator and type-1 plasminogen activator inhibitor in human neoplastic cell lines
17. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells
18. A study of proteases and protease-inhibitor complexes in biological fluids
19. Immunohistochemical localization of urokinase- and tissue-type plasminogen activators in psoriatic skin
20. Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of cell surface urokinase with vinculin
21. Human endothelial cells contain one type of plasminogen activator
22. Immunocytochemical demonstration of tissue-type plasminogen activator in endocrine cells of the rat pituitary gland
23. Tissue-type plasminogen activator in rat medulla
24. Tissue-type plasminogen activator in somatostatin cells of rat pancreas and hypothalamus
25. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
26. Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse
27. Rapid and sensitive colorimetric method for visualizing biotinlabeled DNA probes hybridized to DNA or RNA immobilized on nitrocellulose: bioblots
28. Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts
29. Plasminogen activator inhibitor type-1 protein, mRNA and gene transcription are increased by phorbol esters in human rhabdomyosarcoma cells
30. A tetrazolium method for non-specific alkaline phosphatase
31. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade
32. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells — inhibitor neutralization and one-step affinity purification
33. Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular mass
34. The clonal evolution of tumor cell populations
35. Cloning and sequence of a cDNA coding for the human betamigrating endothelial-cell-type plasminogen activator inhibitor
36. Changes in malignant phenotype of a human carcinoma conditioned by growth environment
37. Endothelial plasminogen activator inhibitor (PAI): a new member of the serpin gene family
38. Immunological relationship between the fast-acting plasminogen activator inhibitors from plasma, blood platelets and endothelial cells demonstrated with a monoclonal antibody against an inhibitor from placenta
39. Distinct localizations of urokinase-type plasminogen activator and its type-1 inhibitor under cultured human fibroblasts and sarcoma cells
40. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts
41. The regulatory region of the human plasminogen activator inhibitor type-1 (PAI-1) gene
42. Cell-assocuated plasminogen activation: Regulation and physiological functions
43. Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma
44. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants
45. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes
46. Studies in a tumor spectrum. III. The effect of phosphoramides on the growth of a variety of mouse and rat tumors
47. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase
48. Purification of fibronectin from human plasma by affinity chromatography under non-denaturing conditions